Abstract 1311P
Background
Lung cancer is the leading cause of cancer-related deaths worldwide. KRAS is the most frequent mutated oncogen in lung adenocarcinoma (LUAD), but it has been recognized as undruggable for many years. KRASG12C inhibitors (KRASG12Ci), are being tested in clinical trials and have revealed promising results in LUAD patients. With these results, two KRASG12Ci have been approved for the treatment of LUAD patients by the FDA, which marks the first approved targeted therapy for KRAS-mutated tumors. While these therapies hold great promise, they face the same limitation as other targeted therapies, the therapeutic potential of these inhibitors can be impaired by resistance. Deciphering intrinsic resistance mechanisms to KRASG12Ci is of prime relevance to predict which patients may benefit from these therapies and to propose therapeutic alternatives.
Methods
The efficacy of two different KRASG12Ci was tested in different KRASG12C-mutated models, in vitro in a panel of 8 LUAD cell lines and 7 PDX-derived organoids (PDXDO) models and in vivo in a panel of 7 patient-derived xenografts (PDX) models. Thus, we define the intrinsic and resistance models, and compare the genomic (WES) and transcriptomic (WTS) data to find a signature that defines the intrinsic resistance to each drug.
Results
Among the 8 LUAD cell lines, we found 3 very sensitive cell lines and 2 intrinsic resistant ones. Among the 7 PDXDO models, we found 4 sensitive models and 3 intrinsic resistant ones. And among the PDX models we found two very sensitive models and two intrinsic resistant ones. These ratios are representative of what was found among patients in clinical trials. Comparative transcriptomic analysis from sensitive and intrinsic resistant models showed different basal levels of expression and/or activation of downstream signaling pathways of KRAS, ARF or PLC and of various receptors such as ERBB, FGFR or IGF-1R.
Conclusions
1) We found a transcriptomic signature that define the intrinsic resistance, characterized by a greater basal expression and/or activation of some RTKs and signaling pathways. 2) We identificate some molecular alterations which could be responsible of the intrinsic resistance and could acts as predictive biomarkers and/or serve as therapeutic targets in combination with KRASG12Ci.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
L.P.A. was funded by the Comunidad de Madrid, CAM, (B2017/BMD3884), AECC, CRIS, ISCIII (PI17/00778; PI20/00820; AC20/0070) and CIBERONC (CD16/12/00442), and co-funded by FEDER from Regional Development European Funds (European Union). I.F. is funded by i+12 and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER from Regional Development European Funds (European Union). A.S. was funded by Ministerio FPU18/06237.
Disclosure
L. Paz-Ares: Financial Interests, Personal, Advisory Board, Speaker fees: Roche, MSD, BMS, AZ, Lilly, PharmaMar, BeiGene, Daiichi, Medscape, Per; Financial Interests, Personal, Advisory Board: Merck Serono, Pfizer, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, Mirati; Financial Interests, Personal, Other, Board member: Genomica, Altum sequencing; Financial Interests, Institutional, Coordinating PI: Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme Corp, BMS, Janssen-Cilag International NV, Novartis, Roche, Sanofi, Tesaro, Alkermes, Lilly, Takeda, Pfizer, PharmaMar; Financial Interests, Personal, Coordinating PI: Amgen; Financial Interests, Other, Member: AACR, ASCO, ESMO; Financial Interests, Other, Foundation Board Member: AECC; Financial Interests, Other, President.ASEICA( Spanish Association of Cancer Research): ASEICA; Financial Interests, Other, Foundation president: ONCOSUR; Financial Interests, Other, member: Small Lung Cancer Group. All other authors have declared no conflicts of interest.
Resources from the same session
1276P - Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Kiyotaka Yoh
Session: Poster session 04
1277P - HRD status of patients with early stage non-small cell lung cancer
Presenter: Apostolos Klinakis
Session: Poster session 04
1278P - ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
Presenter: Ernest Nadal
Session: Poster session 04
1279P - Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
Presenter: Edgar Amorin
Session: Poster session 04
1280P - Comprehensive characterization of human lung squamous cell carcinoma identifies high TFRC expression as a mark of poorly immunogenic tumours
Presenter: María Gutiérrez Pérez
Session: Poster session 04
1281P - Effect of Fra-2 expression on tumour immunogenicity and prognosis in KRAS-mutant lung adenocarcinoma
Presenter: Alvaro Ucero
Session: Poster session 04
1282P - Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Yoshitaka Zenke
Session: Poster session 04
1283P - Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
Presenter: Daniel Hughes
Session: Poster session 04
1284P - Lung cancer among patients with chronic obstructive pulmonary disease: A Danish 10-year observational study of the overlapping population
Presenter: Margrethe Henriksen
Session: Poster session 04
1285P - Lung cancer in never smokers (LCINS): Clinicopathological characteristics and treatment outcomes from a university cancer centre in London
Presenter: Charalampos Gousis
Session: Poster session 04